Interleukin Inhibitors Market Report 2026

Interleukin Inhibitors Market Overview

• Interleukin Inhibitors market size has reached to $57.87 billion in 2025 • Expected to grow to $136.99 billion in 2030 at a compound annual growth rate (CAGR) of 18.9% • Growth Driver: Rising Cases Of Bacterial Infection • Market Trend: Advancements Shaping The Future Of Interleukin Inhibitor Therapies • North America was the largest region in 2025.

What Is Covered Under Interleukin Inhibitors Market?

Interleukin inhibitors refer to a substance used to suppress the immune system that prevents interleukins from working. Interleukins are a class of cytokines produced by white blood cells in response to infection (lymphocytes, monocytes, and macrophages). They are crucial to the control of the immune system. The main types of interleukin inhibitors are IL-17, IL-23, IL-1, IL-5, IL-6, and others. Interleukin 17 is a pro-inflammatory cystine knot cytokine family. In response to IL-23 stimulation, they are produced by a subset of T helper cells known as T helper 17 cells. The different applications include psoriasis, psoriatic arthritis, rheumatoid arthritis, asthma, inflammatory bowel disease, and others, and are distributed through various channels such as hospital pharmacies, retail pharmacies, and online pharmacies.

What Is The Interleukin Inhibitors Market Growth Forecast?

The interleukin inhibitors market size is expected to see rapid growth in the next few years. It will grow to $136.99 billion in 2030 at a compound annual growth rate (CAGR) of 18.9%. The growth in the forecast period can be attributed to development of next-generation biologics, rising investment in personalized immunotherapies, expansion of online pharmacies and telemedicine platforms, increasing regulatory approvals for novel interleukin inhibitors, growing government and healthcare initiatives for chronic disease management. Major trends in the forecast period include rising adoption of interleukin inhibitors for autoimmune disorders, growth in biologic therapies targeting il-17, il-23, il-1, il-5, and il-6, increasing focus on personalized and targeted immunotherapies, expansion of hospital and specialty clinic distribution channels, integration of telemedicine and digital platforms in chronic disease management.

Global Interleukin Inhibitors Market Segmentation

1) By Type: IL-17, IL-23, IL-1, IL-5, IL-6 2) By Application: Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Asthma, Inflammatory Bowel Disease, Other Applications 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies Subsegments: 1) By IL-17: Secukinumab, Ixekizumab, Brodalumab 2) By IL-23: Ustekinumab, Guselkumab, Tildrakizumab 3) By IL-1: Anakinra, Canakinumab 4) By IL-5: Mepolizumab, Reslizumab, Benralizumab 5) By IL-6: Tocilizumab, Sarilumab

What Is The Driver Of The Interleukin Inhibitors Market?

The rising prevalence of bacterial infections is expected to drive the interleukin inhibitors market going forward. Bacterial infections refer to infections caused by bacteria, which are microscopic single-celled organisms. Interleukin inhibitors are extremely helpful in the treatment and prevention of bacterial diseases because they prevent the growth of bacteria. For instance, in March 2024, according to the Centers for Disease Control and Prevention, a US-based government agency, the number of tuberculosis cases rose from 8,320 in 2022 to 9,615 in 2023, reflecting an increase of 1,295 cases. Thus, the rising prevalence of bacterial infections is driving the interleukin inhibitors industry.

Key Players In The Global Interleukin Inhibitors Market

Major companies operating in the interleukin inhibitors market are Sanofi S.A., GlaxoSmithKline plc, Novartis International AG, Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Eli Lilly and Company, AstraZeneca plc, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., AbbVie Inc., Sun Pharmaceutical Industries Limited, Boehringer Ingelheim International GmbH, Janssen Biotech Inc., Ortho Dermatologics, Amgen Inc., Celgene Corporation, Bristol-Myers Squibb Company, Pfizer Inc., Merck & Co. Inc., Takeda Pharmaceutical Company Limited, Biogen Inc., Incyte Corporation, Kyowa Kirin Co Ltd., Astellas Pharma Inc., Ipsen Biopharmaceuticals Inc.

Global Interleukin Inhibitors Market Trends and Insights

Major companies operating in the interleukin inhibitors market are focusing on developing innovative therapies such as monoclonal antibody biosimilar to enhance treatment efficacy, reduce costs, and improve patient accessibility. A monoclonal antibody biosimilar is a biologic product highly similar to an approved reference antibody, with no clinically meaningful differences in safety or efficacy. For instance, in October 2025, Celltrion Inc., a South Korea-based biopharmaceutical company, launched AVTOZMA (tocilizumab-anoh) intravenous (IV) formulation in the United States. The therapy targets interleukin-6 receptors to manage conditions such as rheumatoid arthritis and other inflammatory disorders. By expanding the availability of advanced biologic treatments, the launch aims to improve patient access and clinical outcomes.

What Are Latest Mergers And Acquisitions In The Interleukin Inhibitors Market?

In August 2023, Eli Lilly and Company, a US-based global pharmaceutical company, acquired DICE Therapeutics, Inc., for an undisclosed amount. With this acquisition, Lilly aims to expand its immunology portfolio, accelerate the development of novel therapies, and strengthen its pipeline in autoimmune and inflammatory diseases. DICE Therapeutics, Inc., is a US-based biopharmaceutical company that specializes in developing interleukin inhibitors.

Regional Insights

North America was the largest region in the interleukin inhibitors market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Interleukin Inhibitors Market?

The interleukin inhibitors market consists of sales of anakinra, canakinumab, and rilonacept. Values in this market are ''factory gate values,'' that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Interleukin Inhibitors Market Report 2026?

The interleukin inhibitors market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the interleukin inhibitors industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.